Pfizer files lung cancer drug in the EU, US
Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.
5th April 2018
Latest news
EU green light for Chiesi’s Lamzede
European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
5th April 2018
GSK and Kymera team up for protein degradation alliance
GlaxoSmithKline and Kymera have sealed a pact to work together on the discovery of new medicines based on protein degradation.
5th April 2018
BI snaps up OSE’s novel checkpoint inhibitor
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
5th April 2018
Lilly and Sigilon partner to develop diabetes type I therapies
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for type I diabetes.
5th April 2018
Pfizer, Allogene link to develop cancer therapies
Pfizer and Allogene have entered into an agreement to develop allogeneic CAR T cell therapies.
4th April 2018
Priority review for AZ’ hairy cell leukaemia drug
US regulators have assigned priority review status to AstraZeneca and MedImmune’s moxetumomab pasudotox, which is being developed as a treatment for hairy cell leukaemia (HCL).
4th April 2018
EU expands scope of Amgen’s Xgeva
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
4th April 2018
EU reviews first PARP inhibitor for breast cancer
MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.
4th April 2018
NHS pilots ‘one-stop shops’ for cancer diagnosis
NHS England is rolling out a stream of ‘one-stop shops’ across the country in the hope of speeding up diagnosis of cancer.
4th April 2018
NHS England publishes guidelines curbing OTC prescriptions
NHS England has now published guidelines that could free up to almost £100 million for frontline care every year by culling prescriptions for ‘low-value’ over the counter (OTC) medicines.
3rd April 2018
AZ signs up for access to Compugen’s pipeline
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
3rd April 2018
NHS to fund balloon pulmonary angioplasty in the UK
NHS England is funding a pioneering procedure that will improve treatment outcomes for patients with a lung disease called Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
3rd April 2018
EU reviews for Sanofi’s Dupixent, cemiplimab
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
3rd April 2018
Atopic dermatitis patients to be denied NHS access to Dupixent
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
3rd April 2018
